proteins, which include subunits of CI and CIV, as well as assembly factors for CIII and CIV 1 0 5 [25] [26] [27] . The substrate-binding oxidoreductase of the DRS is the protein CHCHD4, which we 1 0 6 have previously shown to regulate oxygen consumption rates, and hypoxia responses through 1 0 7 effects on HIF signalling [28, 29] . We have also shown that shRNA-mediated silencing of 1 0 8 CHCHD4 reduces the expression of respiratory chain subunits (CI-CIV) in tumour cells [30] 1 0 9 and significantly decreases tumour growth in vivo [28] . In addition, we have shown that 1 1 0 elevated CHCHD4 expression correlates with increased tumour grade and decreased survival 1 1 1 of breast cancer patients, demonstrating an association with disease progression [28] . In this 1 1 2 study we identify mechanisms by which CHCHD4 controls tumour cell proliferation through 1 1 3 its effects on mitochondrial metabolism. CHCHD4 is an essential gene in mice [31] and yeast (Mia40) [32] , and here, we have found 1 1 9 that CHCHD4 is ranked as an essential gene for the proliferation of a panel of 341 tumour 1 2 0 cell lines from the Broad Institute Achilles Project (Fig. 1a ). To better understand the 1 2 1 relationship between CHCHD4 and tumour cell proliferation, we carried out gene set 1 2 2 enrichment analysis (GSEA) on genes that were significantly correlated with CHCHD4 Institute Tumour Cell Line Encyclopaedia). As we anticipated, CHCHD4 was significantly 1 2 5 co-expressed with genes from an OXPHOS gene set 1 2 6 (HALLMARK_OXIDATIVE_PHOSPHORYLATION, Broad Institute) ( Fig. 1b) , including 1 2 7 subunits of CI (NDUFS3) and CIV (COX7C) (Additional File 1: Figure S1a ). Interestingly, 1 2 8 many of the most significantly enriched gene sets correlated with CHCHD4 were those from 1 2 9 proliferative signalling pathways regulated by known oncogenes, including MYC and 1 3 0 mTORC1 (Fig. 1b) . Genes regulated by mTORC1 signalling that were most significantly 1 3 1 1 3 8 ( Fig. 1f ), the most highly correlated genes involved in OXPHOS constituted components of 1 3 9 respiratory chain complexes (e.g. UQCRH, NDUFAB1), as well as enzymes of the TCA cycle 1 4 0 (DLAT, FH), and proteins involved in the general maintenance of mitochondrial function 1 4 1 (e.g. TOMM70, HSPA9). CHCHD4 expression was positively correlated with the expression 1 4 2 of genes regulated by proliferative signalling pathways such as MYC and mTORC1 in each 1 4 3 of the patient cohorts analysed ( Fig. 1c, d , Additional File 1: Figure S1c ). Genes regulated by 1 4 4 mTORC1 signalling that were co-expressed with CHCHD4 in colon adenocarcinoma patient 1 4 5 samples included cell cycle regulators (CCNA2, CDC25A), and genes involved in nucleotide 1 4 6 synthesis (MTHFD2L), suggesting a potential relationship between CHCHD4 expression and 1 4 7 mTORC1 regulation of proliferation ( Fig. 1g ). presence and absence of glutamine. Cells overexpressing CHCHD4 had higher proliferation 2 6 9 rates than control U2OS cells, and glutamine withdrawal abolished this proliferative 2 7 0 advantage ( Fig. 4b ), suggesting the increased rates of proliferation of cells overexpressing 2 7 1 CHCHD4 relied on the availability of glutamine. Furthermore, compared to control U2OS 2 7 2
Thomas et al CHCHD4 regulates a proliferation-EMT switch 9 cells, CHCHD4 (WT)-expressing cells were more significantly lost from culture when 2 7 3 glutamine was withdrawn (Additional File 4: Fig. S4d ), suggesting that tumour cells with 2 7 4 elevated CHCHD4 expression depleted their intracellular glutamine pools more rapidly. We 2 7 5 next interrogated the effects of CHCHD4 expression on glutamine metabolism by culturing 2 7 6 control and CHCHD4 (WT)-expressing cells with uniformly-labelled 13 C5-glutamine, and 2 7 7
analysed both the isotopologue composition and total pool sizes of key glutamine-derived 2 7 8 metabolites. We found that intracellular levels of glutamine and other glutamine-derived 2 7 9 metabolites were lower in CHCHD4 (WT)-expressing cells compared to control U2OS cells, 2 8 0 suggesting greater rates of glutamine consumption (Fig. 4c ). However, there were only very 2 8 1 minor differences in the isotopologue composition of a selection of these metabolites ( overexpressing CHCHD4 (Fig. 4e ), indicating that the increased mTORC1 activity in 2 8 9
CHCHD4 overexpressing cells was dependent on the availability of glutamine. The reduction 2 9 0 in mTORC1 activity could be partially reversed by supplementation of the growth media with 2 9 1 10 mM aspartate ( Fig. 4e) . Similarly, withdrawal of glutamine led to a bigger decrease in 2 9 2 mTORC1 signalling in HCT116 cells than in U2OS cells, which was partially recoverable by 2 9 3 aspartate supplementation (Additional File 4: Figure S4e ). Together these data demonstrate 2 9 4 that CHCHD4 regulates the proliferation of tumour cells through increased glutamine 2 9 5 consumption and mTORC1 signalling. CHCHD4 regulates the EMT phenotype of tumour cells.
9 8
Along with identifying significantly upregulated genes profiles associated to increased 2 9 9 CHCHD4 expression ( Fig. 1) , interestingly, our GSEA also showed that epithelial-3 0 0 mesenchymal transition (EMT)-related genes were amongst the most significantly 3 0 1 downregulated genes associated with increased CHCHD4 expression in both patient samples 3 0 2 ( Fig. 5a , Additional File 5: Figure S5a ) and tumour cell lines (Additional File 5: Figure S5b ). enriched group of proteins ( Fig. 5b) . These included the essential cytoskeletal protein which are well-characterised markers of EMT ( Fig. 5c ) [43, 44] . Furthermore, the second most upregulated protein identified in our SILAC analysis ( Fig. 5c ). We confirmed 3 1 9 some of these EMT protein expression changes in CHCHD4 (WT)-expressing cells by 3 2 0 western blot ( Fig. 5d, e ), while these proteins were unchanged in CHCHD4 (C66A/C68A) (Additional File 5: Figure S5c-d ). Importantly, we found that the transcript levels of VIM and 3 2 5
KRT18 were downregulated and upregulated respectively in cells overexpressing CHCHD4 3 2 6 ( Fig. 5f ), demonstrating that the changes in EMT gene expression are at the level of 3 2 7 transcription, and suggest that elevated CHCHD4 expression in tumour cells leads to a 3 2 8 transcriptional suppression of EMT. Dysregulated metabolism is a common feature of tumour cells, and numerous oncogenes are 3 4 7 potent regulators of metabolic pathways that contribute towards tumour cell proliferation. The mechanisms by which tumour cells maintain biosynthesis of macromolecules for 3 4 9
division are incompletely understood and are currently the focus of intensive investigation.
3 5 0
Here we have identified CHCHD4 as a new regulator of the metabolic drive which supports 3 5 1 tumour cell proliferation, in part through its effects on CI-mediated metabolism of glutamine, for pathways that support biomass accumulation, and these pathways appear to be more 3 5 8
acutely sensitive to perturbations in respiratory chain function than ATP synthesis. Indeed, 3 5 9
here we found that doses of the CI inhibitor BAY 87 2243 that are insufficient to block OCR recent studies have demonstrated that the synthesis of aspartate is an essential function of 3 6 3 mitochondrial respiration for proliferating cells [8, 10] . In agreement with these studies, we 3 6 4
show here that aspartate supplementation is capable of partially reversing the anti- partial, we conclude that other biosynthetic pathways that depend on CI activity and 3 6 8 glutamine availability must also contribute to tumour cell proliferation. For example, both NAD and glutamine are directly involved in nucleotide synthesis [18, 53, 54] , and nucleotide 3 7 0 supplementation in addition to aspartate supplementation may be necessary to fully 3 7 1 recapitulate the proliferation of cells treated with CI inhibitors or glutamine withdrawal. For demonstrating that supporting nucleotide synthesis is an essential role of the mitochondria for 3 7 7
proliferating cells. Indeed, transcriptome analysis of patient samples has identified that 3 7 8 upregulation of nucleotide biosynthetic genes is one of the most common metabolic 3 7 9
alterations across cancer types [57, 58] .
Cancer can be considered a disease of two major phenotypes: dysregulated proliferation, and interactions, and increase motility and resistance to killing by commonly used therapeutics 3 8 4
[59]. In recent years, it has become appreciated that mitochondrial-mediated proliferation and downregulation of mitochondrial OXPHOS, EMT-related genes were the most significantly 3 9 2 upregulated cohort, and these changes were correlated with worse outcomes for patients [57] . In agreement with this, we found that CHCHD4 expression is also positively correlated with 3 9 4 mitochondrial OXPHOS and proliferative signalling pathways (e.g. mTORC1, MYC, E2F), 3 9 5
while it is negatively correlated with an EMT gene signature in vitro and in patient samples. It would appear then that by influencing proliferation which depends on mitochondrial 3 9 7 activity, CHCHD4 also regulates the EMT phenotype of tumour cells through transcriptional 3 9 8
and post-transcriptional mechanisms (e.g. vimentin intracellular distribution). Our results suggest a paradox with respect to the importance of CHCHD4 in cancer. While further investigate the influence of CHCHD4 on the metabolic landscape of cultured tumour (CHCHD4 (WT)-expressing cells) cDNA by puromycin selection using constructs we have 4 5 8
described previously [28] . Human U2OS or human HCT116 colon carcinoma cells were used 4 5 9
to stably express empty GFP Vector (shRNA control 2)) or two independent shRNAs The rabbit anti-puromycin antibody was a gift from Stefan Marciniak (CIMR, Cambridge).
7 8
Uniformly labelled 13 C5-glutamine (CLM-1822-H-MPT-PK) purchased from CK Isotopes.
7 9
Rotenone, antimycin A, DAPI nitrotetrazolium blue, NADH, aspartate, L-lysine, L-arginine, 4 8 0 L-lysine-13 C 6 , 15 N 2 and L-arginine-13 C 6 , 15 N 4 (Arg-10) were purchased from Sigma Aldrich. L-arginine-13 C 6 , 15 N 4 (Arg-10) (heavy) stable isotope labelled amino acids (Sigma Aldrich).
9 9
Media was also supplemented with 10% dialysed FCS (Sigma), penicillin (100 IU/mL), was removed and cells were fixed with 10% trichloroacetic acid (TCA) for 30 min. TCA was 5 1 9
washed with water, wells were allowed to air dry, and then an excess of 0.4% (w/v) SRB in 5 2 0
1% acetic acid was used to stain fixed cells for >10 min. Excess SRB was washed off with which 'day 0' plates fixed with TCA. For drug sensitivity assays, cells were plated in 5 2 5
triplicate columns in 96-well plates, and cultured in maintenance DMEM overnight.
2 6
Appropriate wells were dosed with serial dilutions of compounds, including vehicle control 5 2 7
wells. Cells were incubated for desired time points followed by SRB assay. GI50 values were Microscopy. For immunofluorescence microscopy, cells were seeded onto 13mm diameter 5 3 6 coverslips, and after treatment, were fixed in ice-cold methanol overnight at -20°C. Coverslips were then washed with phosphate buffered saline (PBS). Immunostaining was 5 3 8
carried out by serial incubation using primary antibodies directed to Vimentin (rabbit anti-mouse Alexa-568 secondary antibodies, as well as DAPI (1 μ g/mL). All cell imaging analysis was carried out using Cell Profiler Image analysis software as previously described 5 4 3
[29]. For live cell imaging, cells were imaged using a Nikon 5 4 4
Respirometry. Oxygen consumption rates (OCR) were determined using a Seahorse XF96 5 4 5
Analyser (Seahorse Bioscience). Respiratory profiles were generated by serial treatment with phase was composed of 20cmM ammonium carbonate and 0.1% ammonium hydroxide in isotopologue sum for each metabolite species (proportion of total pool values). (MRC_MC_UU_12022/6).
9 5
Availability of data and materials 5 9 6
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